Gampa Vijaya Kumar1, Rangu mounika2
1Professor and Head, Department of Pharmacy, KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.
2KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.
Recent epidemiological studies have suggested an increased frequency of kidney stone disease in all age groups during the last decades. Although this increase is mostly driven by more frequent diagnosis of idiopathic calcium kidney stone disease, inherited metabolic disorders such as adenine phosphoribosyltransferase (APRT) deficiency, cystinuria, Dent disease, familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), and primary hyperoxaluria (PH), should always be considered in the differential diagnosis of pediatric stone disease. All of the above hereditary disorders cause urinary hyperexcretion of insoluble mineral salts which can lead to recurrent kidney stones or nephrocalcinosis. All of these disorders except cystinuria frequently cause chronic kidney disease (CKD) and can progress to end-stage renal disease (ESRD). Unfortunately, the lack of recognition and knowledge of these diseases has frequently resulted in unacceptable delay in diagnosis and treatment, sometimes with grave consequences. EcliptaProstrata has antiurolithiatic effect against ethylene glycol and Ammonium chloride induced kidney stones in rat kidney tissues. EcliptaProstrata has many pharmacological activities like Anti-mytotoxic, Analgesic, Anti-bacterial, Anti-hepatotoxic, Anti-haemorrhagic, Anti-hyperglycaemic, Anti-oxidant, and Immune modulator.
Keywords: Antiurolithiatic Activity, EcliptaProstrata.